Relay Therapeutics (RLAY) Income from Continuing Operations (2020 - 2025)
Historic Income from Continuing Operations for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to -$74.0 million.
- Relay Therapeutics' Income from Continuing Operations rose 1601.79% to -$74.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$296.8 million, marking a year-over-year increase of 1402.79%. This contributed to the annual value of -$337.7 million for FY2024, which is 123.79% up from last year.
- According to the latest figures from Q3 2025, Relay Therapeutics' Income from Continuing Operations is -$74.0 million, which was up 1601.79% from -$69.7 million recorded in Q2 2025.
- Relay Therapeutics' Income from Continuing Operations' 5-year high stood at -$42.2 million during Q1 2021, with a 5-year trough of -$193.4 million in Q2 2021.
- Its 5-year average for Income from Continuing Operations is -$81.8 million, with a median of -$76.8 million in 2022.
- Per our database at Business Quant, Relay Therapeutics' Income from Continuing Operations crashed by 62369.41% in 2021 and then surged by 6028.65% in 2022.
- Over the past 5 years, Relay Therapeutics' Income from Continuing Operations (Quarter) stood at -$67.5 million in 2021, then dropped by 0.03% to -$67.5 million in 2022, then dropped by 23.74% to -$83.5 million in 2023, then grew by 8.97% to -$76.0 million in 2024, then increased by 2.66% to -$74.0 million in 2025.
- Its last three reported values are -$74.0 million in Q3 2025, -$69.7 million for Q2 2025, and -$77.1 million during Q1 2025.